Connection | Profiles RNS

Search Result Details

Back to Search Results

This page shows the details of why an item matched the keywords from your search.

Search Results

KANTARJIAN, HAGOP M

One or more keywords matched the following items that are connected to KANTARJIAN, HAGOP M

Item Type	Name
Academic Article	Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.
Academic Article	Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy.
Academic Article	Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
Academic Article	Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy.
Academic Article	Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.
Academic Article	RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis.
Academic Article	DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes.
Academic Article	Treatment of myelodysplastic syndromes with AML-type chemotherapy.
Academic Article	Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation.
Academic Article	Acute lymphoblastic leukemia following preleukemic syndromes in adults.
Academic Article	Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model.
Concept	Myelodysplastic Syndromes
Academic Article	Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers.
Academic Article	Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes.
Academic Article	Differences in CD33 intensity between various myeloid neoplasms.
Academic Article	TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.
Academic Article	Pneumonia during remission induction chemotherapy in patients with AML or MDS.
Academic Article	Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.
Academic Article	Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes.
Academic Article	Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.
Academic Article	Clinical significance of plasma endostatin in acute myeloid leukemia/myelodysplastic syndrome.
Academic Article	Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies.
Academic Article	Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy.
Academic Article	A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
Academic Article	Contribution of beta-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS).
Academic Article	Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes.
Academic Article	Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome.
Academic Article	Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
Academic Article	Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.
Academic Article	Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies.
Academic Article	Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Academic Article	Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
Academic Article	Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML).
Academic Article	The role of decitabine in the treatment of myelodysplastic syndromes.
Academic Article	Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes.
Academic Article	Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate.
Academic Article	Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome.
Academic Article	Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy.
Academic Article	Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation.
Academic Article	Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities.
Academic Article	Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes.
Academic Article	Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features.
Academic Article	Feasibility of therapy with hypomethylating agents in patients with renal insufficiency.
Academic Article	The search for better prognostic models in myelodysplastic syndromes.
Academic Article	Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications.
Academic Article	A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.
Academic Article	Mechanisms of resistance to decitabine in the myelodysplastic syndrome.
Academic Article	A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities.
Academic Article	Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.
Academic Article	Randomized, dose-escalation study of the p38a MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome.
Academic Article	Low frequency of H3.3 mutations and upregulated DAXX expression in MDS.
Academic Article	A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome.
Academic Article	Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML.
Academic Article	Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991.
Academic Article	Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes.
Academic Article	Detection of leukemic clone maturation in vivo by premature chromosome condensation.
Academic Article	Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia.
Academic Article	Therapy-related leukemia and myelodysplastic syndrome in chronic lymphocytic leukemia.
Academic Article	Abnormalities in the long arm of chromosome 11 (11q) in patients with de novo and secondary acute myelogenous leukemias and myelodysplastic syndromes.
Academic Article	Myelodysplastic syndrome following successful therapy of acute promyelocytic leukemia.
Academic Article	Topotecan in the treatment of hematologic malignancies.
Academic Article	Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Academic Article	WT1 and GATA1 expression in myelodysplastic syndrome and acute leukemia.
Academic Article	Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Academic Article	Terminal deoxynucleotidyl transferase expression in acute myelogenous leukemia and myelodysplasia as determined by flow cytometry.
Academic Article	11q23 abnormalities in patients with acute myelogenous leukemia and myelodysplastic syndrome as detected by molecular and cytogenetic analyses.
Academic Article	Report of an international working group to standardize response criteria for myelodysplastic syndromes.
Academic Article	Loss of heterozygosity and heterogeneity of its appearance and persisting in the course of acute myeloid leukemia and myelodysplastic syndromes.
Academic Article	Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation.
Academic Article	A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.
Academic Article	Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA.
Academic Article	Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
Academic Article	SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.
Academic Article	Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome.
Academic Article	Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Academic Article	Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.
Academic Article	Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting.
Academic Article	Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia.
Academic Article	A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia.
Academic Article	Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes.
Academic Article	Azacitidine.
Academic Article	Drug insight: emerging new drugs in the treatment of myelodysplastic syndromes.
Academic Article	Clinical experience with decitabine in North American patients with myelodysplastic syndrome.
Academic Article	Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome.
Academic Article	Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.
Academic Article	Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia.
Academic Article	Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
Academic Article	Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy.
Academic Article	Myelodysplastic syndromes: the complexity of stem-cell diseases.
Academic Article	The incidence and impact of thrombocytopenia in myelodysplastic syndromes.
Academic Article	Clofarabine: past, present, and future.
Academic Article	Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
Academic Article	A prognostic score for patients with lower risk myelodysplastic syndrome.
Academic Article	Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome.
Academic Article	A pilot pharmacokinetic study of oral azacitidine.
Academic Article	Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens.
Academic Article	Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome.
Academic Article	Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics.
Academic Article	Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial.
Academic Article	The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?
Academic Article	Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome.
Academic Article	Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome.
Academic Article	Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome.
Academic Article	Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes.
Academic Article	A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.
Academic Article	Pharmacokinetic evaluation of decitabine for the treatment of leukemia.
Academic Article	Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.
Academic Article	Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome.
Academic Article	Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
Academic Article	Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes.
Academic Article	Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine.
Academic Article	Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study.
Academic Article	Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells.
Academic Article	NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes.
Academic Article	Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes.
Academic Article	Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia.
Academic Article	Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.
Academic Article	Therapy-related leukemia and myelodysplastic syndrome.
Academic Article	Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features.
Academic Article	Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16.
Academic Article	Treatment of therapy-related leukemia and myelodysplastic syndrome.
Academic Article	Clinical and prognostic significance of trisomy 21 in adult patients with acute myelogenous leukemia and myelodysplastic syndromes.
Academic Article	Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome.
Academic Article	Lymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell lines.
Academic Article	Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.
Academic Article	Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases.
Academic Article	Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
Academic Article	High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens.
Academic Article	High expression of the receptor tyrosine kinase Tie-1 in acute myeloid leukemia and myelodysplastic syndrome.
Academic Article	Treatment of myelodysplastic syndrome: questions raised by the azacitidine experience.
Academic Article	Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside.
Academic Article	Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome.
Academic Article	Myelodysplastic syndrome is not merely "preleukemia".
Academic Article	Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies.
Academic Article	Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome.
Academic Article	Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes.
Academic Article	Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy.
Academic Article	Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes.
Academic Article	Phase I study of bortezomib in refractory or relapsed acute leukemias.
Academic Article	Novel therapies for myelodysplastic syndromes.
Academic Article	Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies.
Academic Article	Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.
Academic Article	Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib.
Academic Article	Clinical activity of tipifarnib in hematologic malignancies.
Academic Article	Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience.
Academic Article	Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome.
Academic Article	Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Academic Article	The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.
Academic Article	Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis.
Academic Article	A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.
Academic Article	Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys.
Academic Article	Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome.
Academic Article	Targeting DNA methylation.
Academic Article	Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution.
Academic Article	Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome.
Academic Article	Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia.
Academic Article	Cause of death in patients with lower-risk myelodysplastic syndrome.
Academic Article	Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.
Academic Article	Current and future management options for myelodysplastic syndromes.
Academic Article	Thrombocytopenia in patients with myelodysplastic syndromes.
Academic Article	Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy.
Academic Article	Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome.
Academic Article	Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system.
Academic Article	Clinical effect of point mutations in myelodysplastic syndromes.
Academic Article	Association of anemia and cognitive dysfunction in patients with acute myelogenous leukemia and myelodysplastic syndrome.
Academic Article	Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome.
Academic Article	Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system.
Academic Article	Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome.
Academic Article	Revised international prognostic scoring system for myelodysplastic syndromes.
Academic Article	CD30 expression in high-risk acute myeloid leukemia and myelodysplastic syndromes.
Academic Article	Prognostic impact of RAS mutations in patients with myelodysplastic syndrome.
Academic Article	Toll-like receptor alterations in myelodysplastic syndrome.
Academic Article	Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine.
Academic Article	MYBL2 is a sub-haploinsufficient tumor suppressor gene in myeloid malignancy.
Academic Article	CD105 (endoglin) is highly overexpressed in a subset of cases of acute myeloid leukemias.
Academic Article	Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome.
Academic Article	Clofarabine in the treatment of myelodysplastic syndromes.
Academic Article	The prognostic significance of bone marrow levels of neurofibromatosis-1 protein and ras oncogene mutations in patients with acute myeloid leukemia and myelodysplastic syndrome.
Academic Article	Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome.
Academic Article	Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience.
Academic Article	Clofarabine in adult acute leukemias: clinical success and pharmacokinetics.
Academic Article	Azacitidine.
Academic Article	Prognostic significance of monocytosis in patients with myeloproliferative disorders.
Academic Article	Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
Academic Article	A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
Academic Article	Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Academic Article	Recent experience with decitabine in MDS.
Academic Article	Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies.
Academic Article	Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System.
Academic Article	Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years.
Academic Article	Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia.
Academic Article	Decitabine in the treatment of myelodysplastic syndromes.
Academic Article	Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA.
Academic Article	Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
Academic Article	A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias.
Academic Article	FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Academic Article	Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia.
Academic Article	Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes.
Academic Article	AML-associated cytogenetic abnormalities (inv (16), del (16), t(8;21)) in patients with myelodysplastic syndromes.
Academic Article	Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes.
Academic Article	Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia.
Academic Article	Highly reproducible detection and semi-quantification of telomerase activity.
Academic Article	Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome.
Academic Article	Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.
Academic Article	Expression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia.
Academic Article	Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias.
Academic Article	A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome.
Academic Article	Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine.
Academic Article	The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes.
Academic Article	Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy.
Academic Article	Ubiquitin-proteasome system profiling in acute leukemias and its clinical relevance.
Academic Article	Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.
Academic Article	Integrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution.
Academic Article	Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis.
Academic Article	The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes.
Academic Article	A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia.
Academic Article	Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia.
Academic Article	Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial.
Academic Article	Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes.
Academic Article	Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes.
Academic Article	Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
Academic Article	Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium.
Academic Article	A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes.
Academic Article	Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.
Academic Article	Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
Academic Article	Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM).
Academic Article	Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up.
Academic Article	TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
Academic Article	Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome.
Academic Article	Comprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment.
Academic Article	TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis.
Academic Article	Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival.
Academic Article	Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
Academic Article	Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.
Academic Article	Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center.
Academic Article	Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
Academic Article	Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study.
Academic Article	Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions.
Academic Article	Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion.
Academic Article	IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression.
Academic Article	Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome
Academic Article	Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes
Academic Article	Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents
Academic Article	TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases
Academic Article	Decitabine in myelodysplastic syndromes
Academic Article	A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials
Academic Article	The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure
Academic Article	CD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast count
Academic Article	Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher risk myelodysplastic syndromes
Academic Article	IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression
Academic Article	Hypomethylating strategies in leukemia and myelodysplastic syndromes
Academic Article	Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides
Academic Article	Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia
Academic Article	Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
Academic Article	A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome
Academic Article	Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
Academic Article	Unraveling Myelodysplastic Syndromes
Academic Article	The incidence and impact of thrombocytopenia in myelodysplastic syndrome
Academic Article	Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents
Academic Article	A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes
Academic Article	Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia [2]
Academic Article	The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes
Academic Article	Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
Academic Article	Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes
Academic Article	Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME)
Academic Article	Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion
Academic Article	A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.
Academic Article	A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.
Academic Article	Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome.
Academic Article	A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome.
Academic Article	Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.
Academic Article	Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.
Academic Article	CD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast count.
Academic Article	Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Academic Article	Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.
Academic Article	Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents.
Academic Article	Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup.
Academic Article	Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.
Academic Article	The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure.
Academic Article	Time-dependent changes in mortality and transformation risk in MDS.
Academic Article	Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents.
Academic Article	Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents.
Academic Article	Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study.
Academic Article	Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes.
Academic Article	Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia.
Academic Article	KIR gene haplotype: an independent predictor of clinical outcome in MDS patients.
Academic Article	Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes.
Academic Article	An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes.
Academic Article	Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.
Academic Article	The emerging role of immune checkpoint based approaches in AML and MDS.
Academic Article	A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.
Academic Article	Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies.
Academic Article	Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care.
Academic Article	Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.
Academic Article	Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome.
Academic Article	Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS.
Academic Article	Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.
Academic Article	Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Academic Article	Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.
Academic Article	Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Academic Article	A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome.
Academic Article	A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents.
Academic Article	Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R.
Academic Article	Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation.
Academic Article	Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome.
Academic Article	Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS.
Academic Article	Hematologic malignancies and Li-Fraumeni syndrome.
Academic Article	Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice.
Academic Article	Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome.
Academic Article	An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study.
Academic Article	NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy.
Academic Article	Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts.
Academic Article	Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial.
Academic Article	Philadelphia chromosome-negative acute leukemia in patients with chronic myeloid leukemia.
Academic Article	Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation.
Academic Article	Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.
Academic Article	CPX-351 (vyxeos) in AML.
Academic Article	Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes.
Academic Article	t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm?
Academic Article	Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes.
Academic Article	LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents.
Academic Article	Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy.
Academic Article	Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial.
Academic Article	Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors.
Academic Article	Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study.
Academic Article	Results of a Phase 1/2a dose-escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes.
Academic Article	Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study.
Academic Article	Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities.
Academic Article	Treating Leukemia in the Time of COVID-19.
Academic Article	Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3).
Academic Article	Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy.
Academic Article	Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial.
Academic Article	Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes.
Academic Article	Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications.
Academic Article	Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis.
Academic Article	Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Academic Article	Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS).
Academic Article	Activity of venetoclax-based therapy in chronic myelomonocytic leukemia.
Academic Article	A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.
Academic Article	Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation.
Academic Article	Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes.
Academic Article	Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.
Academic Article	Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome.
Academic Article	Time to blur the blast boundaries.
Academic Article	Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure.
Academic Article	The Evolution of Research and Therapy With Hypomethylating Agents in Acute Myeloid Leukemia and Myelodysplastic Syndrome: New Directions for Old Drugs.
Academic Article	Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: Past discoveries and future directions.
Academic Article	Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome.
Academic Article	TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions.
Academic Article	Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study.
Academic Article	Biologic features and clinical outcomes in newly diagnosed myelodysplastic syndrome with KMT2A rearrangements.
Academic Article	TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity.
Academic Article	High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance.
Academic Article	Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia.
Academic Article	Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.
Academic Article	Characteristics of patients with myelodysplastic neoplasm and spliceosome mutations.
Academic Article	A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.
Academic Article	Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure.
Academic Article	Early Mortality as a Quality Indicator in Frontline and Salvage Acute Myeloid Leukemia.
Academic Article	Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents.
Academic Article	Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.
Academic Article	Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax.
Academic Article	Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study.
Academic Article	Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS.
Academic Article	Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome.

Search Criteria

Myelodysplastic Syndromes